Advanced searches left 3/3

Ace Inhibitor - Crossref

Summarized by Plex Scholar
Last Updated: 10 November 2022

* If you want to update the article please login/register

ACE-inhibitors: a preventive measure for bone flap resorption after autologous cranioplasty?

OBJECTIVE Decompressive craniectomy is a common treatment for chronic intracranial hypertension. METHODS In this single-center, retrospective study 183 cases were evaluated for bone flap resorption after AC, according to this single-center, retrospective review. The log-rank test and Univariate Kaplan-Meier's report revealed that ACEI and ventriculoperitoneal shunt treatment were associated with reduced incidences of BFR. Multiple Cox regression results showed ACEI therapy, VP shunt therapy, and male sex to be reduced risk of BFR, but bone fragmentation was a greater risk of BFR. CONCLUSIONS Hypertensive patients treated with ACEIs have a lower incidence of BFR than those treated with other hypertensive medications and nonhypertensive patients. Our findings are in accordance with recent studies indicating that ACEIs have a positive influence on bone healing and preservation. In a multicenter prospective trial, a further investigation of the correlation between ACEI treatment and BFR formation is required and will be evaluated.

Source link: https://doi.org/10.3171/2018.6.jns172605


ACE Inhibitor or Angiotensin II Receptor Antagonist Attenuates Diabetic Neuropathy in Streptozotocin-Induced Diabetic Rats

We investigated cardiovascular and neural responses in streptozotocin-induced diabetic rats treated for ten weeks with enalapril, an ACE inhibitor, or l-158809, an angiotensin II receptor blocker. In all groups of untreated diabetic rats, endoneurial blood flow and motor nerve conduction were reduced. Diabetes-induced decrease in endoneurial blood flow and MNCV in group 1, diabetes-induced decrease in diabetes-induced decrease in endoneurial blood flow and MNCV in group 1. In groups 2u20134, enalapril intervention was more effective in reversing diabetes-induced elevation in endoneurial blood flow and MNCV than l-158809. In all groups, the treatment of diabetic rats with enalapril or l-158809 reduced the superoxide level in the aorta, but was less effective in epineurial arterioles. These findings show that ACE inhibitors and/or angiotensin II receptor blockers may be safe treatments for diabetes and vascular and neural dysfunction.

Source link: https://doi.org/10.2337/diabetes.55.02.06.db05-0885


Modulation of Incipient Glomerular Lesions in Experimental Diabetic Nephropathy by Hypotensive and Subhypotensive Dosages of an ACE Inhibitor

The aim of this research was to determine the effect of hypotensive and subcutaneous doses of the ACE inhibitor quinapril ex vivo and of its active metabolite quinaprilat in vitro on the glomerular albumin permeability defect in the early stages of experimental diabetes. Six groups of male Wistar rats were monitored for four weeks as part of an ex vivo study. The glomerular filtration rate and systolic blood pressure and the glomerular filtration rate were observed by Dosage-dependent effects of quinapril on systolic blood pressure and the glomerular filtration rate. Compared to results in control glomeruli, quinaprilat reduced Palb by a substantial amount in concentration ranges from 10 to 10 mol/l in the in vitro study. These research findings showed that ACE inhibitor therapy prevents the premature onset of the Palb defect in experimental diabetes early in life.

Source link: https://doi.org/10.2337/diabetes.50.11.2619


ACE (Angiotensin-Converting Enzyme) Inhibitors/Angiotensin Receptor Blockers Are Associated With Lower Colorectal Cancer Risk

It's unclear if ACE inhibitors and angiotensin receptor blockers will raise colorectal cancer risk. Following a negative baseline colonoscopy, we wanted to find an association between their use and colorectal cancer risk. Colorectal cancer, prior colorectal cancer, inflammatory bowel disease, and prior colectomy were among the exclusion criteria. The colorectal cancer sites were classified as both proximal and distal cancer. The adjusted hazard ratio of colorectal cancer with ACE inhibitor/angiotensin receptor blocker use was calculated by a propensity score regression adjustment of 23 covariates. These drugs were shown to reduce the risk of colorectal cancer among those who died fewer than three years after index colonoscopy, but not colorectal cancer that occurred more than three years; every single year rise in the drug use was associated with a 5% decrease in adjusted hazard ratio risk. In a time-response manner, ACE inhibitors/angiotensin receptor blocker were associated with a reduced colorectal cancer risk in a duration-response manner.

Source link: https://doi.org/10.1161/hypertensionaha.120.15317


Determinants and clinical outcome of uptitration of ACE-inhibitors and beta-blockers in patients with heart failure: a prospective European study

We wanted to investigate the clinical outcomes of patients with HFrEF who did not meet the recommended treatment doses of ACE-inhibitors/Angiotensin receptor blockers and/or beta-blockers, as well as treatment-indication-bias. Methods and findings BIOSTAT-CHF was specifically developed to investigate uptitration of ACE-inhibitors/ARBs and/or beta-blockers in 2516 heart failure patients from 11 European countries who were randomly chosen if they were underoptimally treated, and encouraging research was planned and encouraged. Patients with a LVEF > 40% were refused to patients with patients who died during the uptitation period or patients with a LVEF > 40%. Patients achieving 50 percent of the recommended ACE-inhibitor/ARB and/or beta-blocker dose had similar risk of death and/or heart failure hospitalization to those who did not reach u265100%. Patients with HFrEF who were treated with less than half of the recommended dose of ACE-inhibitors/ARBs and beta-blockers were at a higher risk of death and/or heart failure hospitalization in comparison to patients who were not achieving u2265100%.

Source link: https://doi.org/10.1093/eurheartj/ehx026


In vitro assay of ACE Inhibitor, Antidiabetic and Antioxidants activities from Indonesia Traditional Medicine (Jamu)

Hypertension in diabetic patients with diabetes causes heart and kidney disease problems that have exacerbated. Angiotensin Converting Enzyme inhibitors are the first-choice treatment of hypertension in diabetic patients. Herbal medicine, a native Indonesian drug, has been used for many ailments, including hypertension and diabetes mellitus, for over a long time. jamu met the requirements of both specific and non-specific parameters, alpha-glucosidase enzyme inhibitors, and antioxidants kinetic activity with IC50 values of 103. 75 — 103. 75 w/ml, 49. 95 xu00b5g/ml, 11. 4 g/ml, and antioxidant activity with IC50 values of 103. 75 u00b5g/ml, 11. 4 g/ml.

Source link: https://doi.org/10.52711/0974-360x.2022.00708


Molecular Docking of Active Compounds from Traditional Medicinal Plants as ACE-2 protein (1R4L) inhibitor in searching for COVID-19 drug

COVID-19, a worldwide pandemic triggered by severe acute respiratory syndrome coronavirus-2, is a global pandemic caused by severe acute respiratory syndrome coronavirus-2. SARS-CoV-2 binds to ACE-2's receptor binding-domain. The number of COVID-19 cases is still growing, but only 2. 5% of Indonesians are fully vaccinated, yet just 2. 5% of Indonesians are fully vaccinated. However, many common medicinal plants have the ability to convert COVID-19 drugs. Also, this research sought to investigate several active compounds derivate from the traditional medicinal plant as an inhibitor of SARS-CoV-2 receptor in human cells referred to as ACE2. According to this report, indirubin had lower binding energy as compared to sulains A and MLN-4760 as comparative control and potent inhibitor control, respectively. Indiribin reported similar behavior with amino acid residues to ACE-2 as compared to placebo. Indirubin could be produced as a promising drug for COVID-19 antiviral drugs, based on the research findings.

Source link: https://doi.org/10.52711/0974-360x.2022.00712


Impact of ACE Inhibitors and AII Receptor Blockers on Peritoneal Membrane Transport Characteristics in Long-Term Peritoneal Dialysis Patients

Background Long-term peritoneal dialysis can lead to peritoneal fibrosis and ultrafiltration failure. Angiotensin-II is known to be a growth factor in fibrosis, and a number of animal studies have found it likely that reducing the effects of AII by angiotensin-converting enzyme or angiotensin receptor blocker can attenuate these difficulties. Patients and Setting We reviewed data from 66 patients treated with PD therapy at our center for at least two years, during which time at least two standard peritoneal permeability tests were performed. Time course of peritoneal transport in the ACE/ARB group had decreased, while in the control group, the number had increased. The duration of PD therapy affected the creatinine's mass transfer area coefficient, but this interaction was different with respect to the use of ACE/AII inhibitors.

Source link: https://doi.org/10.1177/089686080702700413


Protein Hydrolysates from Brewing By-Products as Natural Alternatives to ACE-Inhibitory Drugs for Hypertension Management

Angiotensin-converting enzyme inhibitors are anti-hypertensive drugs with a variety of side effects. The aim of this research was to simulate oral administration to determine BSG/BSY peptides' effectiveness by submitting protein hydrolysates sequentially to simulate gastrointestinal digestion, intestinal absorption, and liver metabolism. To determine BSG/BSY protein hydrolysates safeness, MTT assay was used. Initial and final protein hydrolysates were tested with a fluorometric assay and compared to captopril. Simulation of oral administration greatly enhanced the BSY and MIX protein hydrolysates (u2019 ACE-inhibitory capacity, but final MIX and BSG demonstrated greater ACE-inhibitory capacity than captopril.

Source link: https://doi.org/10.3390/life12101554


Effects of ACE Inhibitor (Lisinopril) with Folic Acid Supplementation in the Management of Hypertension Associated with Hyperuricemia

Aims & Objectives: To determine the efficacy of ACE inhibitors alone and with the folic acid on systolic and diastolic blood pressure & serum uric acid level. In the case study group after therapy, there was 118 u00b1 6. 12 mmHg, which was the mean value of systolic B. P in the control group after treatment was 144 b1 4. 9. Although in the case study group, the serum uric acid level after treatment in the control group was 6. 7 mg/dl, not 5. 11 mg/dl; in the case study group, it was 5. 11 mg/dl. Although in the case study group, the treatment in the control group was 12. 31 u00b1 2. 89, while in the case study group it was 27. 09 nmol/L. Conclusion: Folic acid elevates the effectiveness of an ACE inhibitor and plays a significant role in the reduction of serum uric acid as a therapeutic agent in the cases of mild to moderate hypertension related to hyperuricemia.

Source link: https://doi.org/10.9734/jpri/2022/v34i20a35825

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions